Table 2.
Patient and treatment information of the patients in the Endoresist cohort
| Patients N = 62a | |
|---|---|
| Age at primary diagnosis | |
| Median, years (range) | 61 (30-88) |
| Surgical procedure primary tumor | |
| Mastectomy | 30 (48.39%) |
| Sector excision | 31 (50.00%) |
| N/A | 1 (1.61%) |
| Adjuvant endocrine therapy | |
| Tamoxifen | 33 (53.23%) |
| Aromatase inhibitor | 24 (38.71%) |
| Other | 5 (8.06%) |
| Adjuvant chemotherapy | |
| Received | 32 (51.61%) |
| Not received | 30 (48.39%) |
| Adjuvant radiotherapy | |
| Received | 40 (64.52%) |
| Not received | 22 (35.48%) |
| Relapse location | |
| Ipsilateral | 22 (35.48%) |
| Contralateral no DCIS | 5 (8.06%) |
| Contralateral to DCIS | 14 (22.58%) |
| Distant metastasis | 21 (33.87%) |
| Distant metastasis location (N = 21) | |
| Colorectal | 1 (4.75%)b |
| Contralateral axilla | 1 (4.75%)b |
| Liver | 6 (28.57%)b |
| Lung | 2 (9.52%)b |
| Skeleton | 6 (28.57%)b |
| Skin | 3 (14.29%)b |
| Ovary | 2 (9.52%)b |
DCIS ductal carcinoma in situ, N/A data not available.
aAll samples, even if lacking DNA or RNA data.
bPercentages out of the patients with distant metastases (N = 21).